Evidence map›Paper›PMID 40649729›Full record

Trial reportInternational journal of molecular sciences2025

Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.

László Imre Tóth, Adrienn Harsányi, Sára Csiha, Ágnes Molnár, Hajnalka Lőrincz, Attila Csaba Nagy, György Paragh, Mariann Harangi, Ferenc Sztanek

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

László Imre TóthDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Adrienn HarsányiDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Sára CsihaDoctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
Ágnes MolnárDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Hajnalka LőrinczDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0009-0000-5303-3082
Attila Csaba NagyDepartment of Health Informatics, Faculty of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0002-0554-7350
György ParaghDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Mariann HarangiDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0001-9761-9595
Ferenc SztanekDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.

Funding

National Research, Development and Innovation Office - NKFIH K142273
6 · The paper itself

Abstract

Recent studies have demonstrated the efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in enhancing glycemic control, regulating body weight, and modulating lipid metabolism. However, their effects on lipoprotein subfractions have not been clarified. The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM). A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsLipidsAdultAgedBlood GlucoseBody Mass IndexFemaleFollow-Up StudiesGlucagon-Like Peptide 1Glycated HemoglobinHumansLipid MetabolismMaleMiddle AgedBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsLipidsSemaglutideSitagliptin Phosphatecardiometabolic riskGLP-1 receptor agonistlipoprotein subfractionssemaglutidesitagliptintype 2 diabetes mellitus

Identifiers

PMID40649729
PMCPMC12250273

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.